Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.

Hisao ImaiSatoshi WasamotoOu YamaguchiKensuke SuzukiTomohide SugiyamaJunji UchinoHiroyuki MinemuraTakashi OsakiHisashi IshiiYukihiro UmedaKeita MoriMie KotakeHiroshi KagamuNobutoshi MorozumiHirokazu TaniguchiTakashi KasaiKoichi MinatoKyoichi Kaira

Published in: Journal of cancer research and clinical oncology (2019)

Elderly patients with NSCLC expressing high PD-L1 tolerated front-line pembrolizumab monotherapy well. Their survival outcomes were equivalent to those of younger patients. In patients with non-PD, first-line pembrolizumab monotherapy may improve PFS; in conjunction with good PS, it additionally improves OS.

Keyphrases

advanced non small cell lung cancer
combination therapy
end stage renal disease
open label
ejection fraction
small cell lung cancer
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
randomized controlled trial
clinical trial
study protocol